| AC3-I/AC3-C α–MHC promoter transgenic [9,11]
|
Cardiomyopathy resistance to MI, isoproterenol infusion and angiotensin II. |
| CaMKIIN α–MHC promoter transgenic [80]
|
Reduced myocardial NF-κB signaling |
| CaMKIIδB α–MHC promoter transgenic [1,2]
|
Hypertrophy and secondary cardiomyopathy |
| CaMKIIδC α–MHC promoter transgenic [2–4]
|
Spontaneous cardiomyopathy, arrhythmias, and sudden death |
| CaMKIV α–MHC promoter transgenic [16]
|
Elevated myocardial CaMKII, hypertrophy and proarrhythmia |
| CaMKIIδ−/− Global knockout [6,7]
|
Resistance to aortic banding induced cardiomyopathy |
|
CaMKIIγ−/− Global knockout [12]
|
Reduced macrophage and endothelial cell apoptosis in response to ER stress |
